PEDIATRICS Vol. 81 No. 6 June 1988, pp. 749-755
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vichinsky, E.
Right arrow Articles by Lubin, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vichinsky, E.
Right arrow Articles by Lubin, B.

Newborn Screening for Sickle Cell Disease: Effect on Mortality

Elliott Vichinsky MD1, Deborah Hurst MD1, Ann Earles RN, PNP1, Klara Kleman MT, MS1, and Bertram Lubin MD1

1 From the Department of Hematology/Oncology, Children's Hospital, Oakland, California

Newborn screening for sickle cell disease has been recommended as a method of decreasing patient mortality. However, its effectiveness in accomplishing this has not been reliably measured. To help determine the effectiveness, 10 years of experience in newborn screening have been summarized. The effects of early patient enrollment in a comprehensive treatment program on long-term morbidity and mortality are reported. From 1975 to 1985, 84,663 newborns were screened regardless of race or ethnic background. Bart's hemoglobin was present in 5%, hemoglobin AS in 2.6%, and hemoglobin AC in 0.75%. Excluding Bart's, approximately 3.6% of all newborns were carriers for hemoglobinopathy. Sickle cell disease occurred in 1:951 births (58 hemoglobin SS, 25 hemoglobin FSC, three hemoglobin S-beta+-thalassemia, and three hemoglobin S-beta°-thalassemia). In addition, one in every 4,233 newborns had a clinically significant thalassemia syndrome (eight hemoglobin FE, ten hemoglobin F only, two hemoglobin H). Compared with other newborn screening programs in California, (congenital hypothyroidism, 1:3,849; phenylketonuria 1:22,474, galactosemia 1:74,103), hemoglobinopathies are the most prevalent congenital disease. Eighty-one newborns with sickle cell disease were followed for 7.2 years. Patients experienced 513 hospitalizations, including 13 episodes of sepsis with or without meningitis and ten acute sequestration crises. The overall mortality rate for patients with sickle cell anemia diagnosed in the newborn period was 1.8%. In comparison, the clinical course of 64 patients with sickle cell anemia diagnosed after 3 months of age and followed for an average of 9.4 years was analyzed. Five of these patients died. In two of these, sickle cell anemia was diagnosed at the time of the death. Overall mortality rate in this group was 8%. In summary, the data indicate that newborn screening, when coupled with extensive follow-up and education, will significantly decrease patient mortality.

Key Words: newborn screening • sickle cell disease • sepsis • anemia • hemoglobinopathy

Submitted on November 5, 1987
Accepted on January 4, 1988




This article has been cited by other articles:


Home page
 haematolHome page
I. Roberts and M. de Montalembert
Sickle cell disease as a paradigm of immigration hematology: new challenges for hematologists in Europe
Haematologica, July 1, 2007; 92(7): 865 - 871.
[Full Text] [PDF]

Home page
 Canadian J. AnesthesiaHome page
M. W. Crawford, S. Galton, and M. Abdelhaleem
REPLY
Can J Anesth, June 1, 2006; 53(6): 632 - 633.
[Full Text] [PDF]

Home page
 Canadian J. AnesthesiaHome page
M. W. Crawford, S. Galton, and M. Abdelhaleem
Preoperative screening for sickle cell disease in children: clinical implications: [Depistage preoperatoire de la drepanocytose chez les enfants : implications cliniques]
Can J Anesth, December 1, 2005; 52(10): 1058 - 1063.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. T. Quinn, Z. R. Rogers, and G. R. Buchanan
Survival of children with sickle cell disease
Blood, June 1, 2004; 103(11): 4023 - 4027.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
S. Claster and E. P Vichinsky
Managing sickle cell disease
BMJ, November 15, 2003; 327(7424): 1151 - 1155.
[Full Text] [PDF]

Home page
 BloodHome page
M. C. Rahimy, A. Gangbo, G. Ahouignan, R. Adjou, C. Deguenon, S. Goussanou, and E. Alihonou
Effect of a comprehensive clinical care program on disease course in severely ill children with sickle cell anemia in a sub-Saharan African setting
Blood, August 1, 2003; 102(3): 834 - 838.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
Section on Hematology/Oncology and Committee on Ge
Health Supervision for Children with Sickle Cell Disease
Pediatrics, March 1, 2002; 109(3): 526 - 535.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
M. Campbell, J. S. Henthorn, and S. C. Davies
Evaluation of Cation-Exchange HPLC Compared with Isoelectric Focusing for Neonatal Hemoglobinopathy Screening
Clin. Chem., July 1, 1999; 45(7): 969 - 975.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
M. H. Steinberg
Management of Sickle Cell Disease
N. Engl. J. Med., April 1, 1999; 340(13): 1021 - 1030.
[Full Text] [PDF]

Home page
 ScienceHome page
N. A. Holtzman, P. D. Murphy, M. S. Watson, and P. A. Barr
Predictive Genetic Testing: From Basic Research to Clinical Practice
Science, October 24, 1997; 278(5338): 602 - 605.
[Abstract] [Full Text]

Home page
 J Holist NursHome page
B. Houser, H. M. Plawecki, J. Carr, M. A. Smith, and J. A. Plawecki
A Holistic Approach to Vaso-Occlusive Pain Crisis in Children With Sickle Cell Disease
J Holist Nurs, March 1, 1992; 10(1): 62 - 75.
[Abstract] [PDF]